MYC and non-small cell lung carcinoma: CAPE and docetaxel treatment together significantly reduced the expression of SKP2, c-MYC, and phospho-EGFR (Tyr 992) proteins in NSCLC compared to either CAPE or docetaxel treatment alone [192].